Stocks that tracked hedge funds and asset managers added to or newly bought in their latest 13F filings, while retail attention is still low — with the fund-by-fund share changes, estimated entry prices and an AI read on why they may be buying.
Next scan: tomorrow by 9:00 AM ET. A new scan is posted every Saturday by 9:00 AM ET.
5stocks qualified
4funds adding
5new positions
$4.14Bheld by those funds
AIThis scan
We compared 13F-HR filings across five managers — Berkshire Hathaway, Bridgewater Associates, Renaissance Technologies, Citadel Advisors, and Two Sigma — spanning the Q2-26 window (period ending 2026-06-30, filed August) versus Q1-26 (period ending 2026-03-31). All five funds returned complete holdings via EDGAR; no filer failed. After collapsing per-CUSIP across split lots, excluding puts (which are hedges, not bullish accumulation), and filtering out sector ETFs, SPACs, the AAPL/MSFT/NVDA/GOOG/META/AMZN/TSLA mega-cap retail set, and Berkshire's own stock, five names cleared both the acceleration gate (≥2 funds adding or newly opening with ≥25% aggregate share growth) and the retail-attention gate (Google Trends under ~25, muted news flow, absent from retail hotlists, no obvious options squeeze setup). The single most surprising finding: three of the four quant/multi-strat funds in the watchlist opened entirely new Intercontinental Exchange positions in Q2-26 — a synchronized Q2 initiation that is rare. Berkshire's own biggest Q2 moves (Alphabet, Delta, Macy's, Lennar) were deliberately excluded — GOOG/GOOGL fail the retail-quiet filter despite being Buffett block buys, and the rest were Berkshire-only among this watchlist and lack cross-fund confirmation. All five published names were strictly held in both filings or flagged as new positions, and none report earnings within 7 trading days of this scan.
How this scan was run
Per-CUSIP delta analysis across the five-fund watchlist. For each CUSIP in any manager's Q2-26 filing, we summed shares across split-lot rows, subtracted the Q1-26 count (zero = new), and kept only CUSIPs where (a) at least two funds added or newly opened AND (b) aggregate share count across the adders either grew ≥25% quarter-over-quarter or included at least two outright new positions. Put-option entries excluded (puts hedge, not accumulate); common and call positions kept. Standard quality rails applied: market cap over $1B, average daily dollar volume over $10M, no earnings within 7 trading days, no sector ETFs, SPACs, or leveraged products. Quant managers (Renaissance, Two Sigma, and the market-making side of Citadel) are flagged as partial signal because their 13Fs are quarter-end snapshots and often obscure heavy intra-quarter trading; we therefore require their adds to be corroborated by at least one slower-moving manager or by multiple quants synchronizing. CUSIP→ticker resolved via SEC company_tickers.json plus issuer-name matching; no dual-class ambiguity remained in the final five. The avgEntryPriceEstimate field is a quarter-end mark (filing valueUsd ÷ sharesHeld), not actual cost basis — 13F reports value at period-end only.
#1
ICE
Intercontinental Exchange Inc.
FinancialsMkt cap $89.7BNext earnings Oct 30, 2026
Price
$156.19
Est. fund entry
$123.11+26.9%
Shares held
6.56M
Position value
$807.7M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
—
38.9K
New position
Renaissance Technologies
—
1.27M
New position
Citadel Advisors
1.86M
3.22M
+73.3%
Two Sigma Investments
—
2.03M
New position
Retail attention 4 of 4 signals quiet
Google Trends14/100quiet
News, 30 days11 articlesquiet
Call/put OI1.30quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
ICE is the only name on this scan where three of four watchlist quant/multi-strat managers opened entirely new positions in the same quarter — Bridgewater, Renaissance, and Two Sigma all held zero shares in Q1-26 and sized up to $4.8M, $156M, and $250M respectively by Q2-26, while Citadel grew its existing stake 73% to over $397M. ICE owns the NYSE, the global derivatives rails for Brent and the CDS complex, and the Black Knight mortgage-tech business — a classic toll-booth model with pricing power. Synchronized Q2 initiations across funds that rarely agree suggest desks are modeling sustained macro volatility (fuels transaction revenue) alongside the mortgage-tech cross-sell inflecting just as rate-cut data starts re-animating origination activity. The catalyst retail has not priced: the mortgage origination segment turning from drag to tailwind, a story that lags the broader rates narrative by one or two prints.
What would prove it wrong
The rate-cut path is non-linear; a stall in origination keeps the mortgage-tech thesis dormant for another two quarters. Q3 earnings around Oct 29-Nov 2 are outside the 7-trading-day exclusion window but close enough to reset the setup.
#2
MDT
Medtronic plc
Health CareMkt cap $112.8BNext earnings Nov 23, 2026
Price
$88.48
Est. fund entry
$78.23+13.1%
Shares held
13.1M
Position value
$1.02B
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
255.2K
482.5K
+89.0%
Renaissance Technologies
—
3.17M
New position
Citadel Advisors
2.45M
6.20M
+153.1%
Two Sigma Investments
626.9K
3.24M
+417.0%
Retail attention 4 of 4 signals quiet
Google Trends17/100quiet
News, 30 days12 articlesquiet
Call/put OI1.10quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Renaissance opened a $248M Medtronic stake from zero in Q2-26 while Citadel added 153%, Two Sigma 417%, and Bridgewater 89% — all four marked near $78 at quarter-end. The stock prints $88 today, so the desks are already up ~13% on the add and have not been chased. Medtronic spent two years restructuring around diabetes and structural heart, refocusing capital toward Hugo robotic surgery and pulsed-field ablation; the synchronized Q2 build suggests fund modelers see the Street's complacent 'ex-growth MedTech' framing as the mispricing. Catalyst retail has not priced: renal denervation reimbursement expansion and PFA share gains against Boston Scientific flowing through the November fiscal Q2 2027 print, which medical-device trade reporters have been tracking but mainstream equity media has largely ignored.
What would prove it wrong
The ~13% move off the fund marks already compresses margin of safety; a retail wake-up on the November print could close the gap fast. Competitive pulsed-field setup against BSX and JNJ remains the structural overhang.
#3
MCK
McKesson Corporation
Health CareMkt cap $117.3BNext earnings Nov 4, 2026
Price
$938.84
Est. fund entry
$755.60+24.3%
Shares held
1.04M
Position value
$787.9M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
67.4K
70.4K
+4.4%
Renaissance Technologies
117.2K
361.1K
+208.0%
Citadel Advisors
189.7K
601.8K
+217.2%
Two Sigma Investments
6.20K
9.45K
+52.4%
Retail attention 4 of 4 signals quiet
Google Trends9/100quiet
News, 30 days8 articlesquiet
Call/put OI1.00quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
All four non-Berkshire managers added McKesson aggressively in Q2-26 — Citadel 217%, Renaissance 208%, Two Sigma 52%, Bridgewater 4% — at a quarter-end mark near $756. The stock trades $939 today, meaning desks have already captured a ~24% move with no retail participation on the way up. The pharmacy-distribution oligopoly (MCK, COR, ABC) is one of the densest opex-arbitrage businesses in the S&P and almost never draws retail flow because the model is unglamorous. Quiet accumulation across funds that rarely agree likely reflects (a) biosimilar and GLP-1 unit volume rolling through the US Pharmaceutical segment and (b) specialty-oncology bolt-on acquisitions widening Rx-services margins. Catalyst retail has not priced: specialty-oncology margin uplift surfacing in the November 4 fiscal Q2 2027 print, buried under the surface of a 'boring distribution' narrative.
What would prove it wrong
Fund marks are stale after a 24% rally; new entries forfeit most of the fund's margin of safety. The DOJ opioid-settlement overhang can periodically re-emerge as a sector-wide headline risk.
#4
KMB
Kimberly-Clark Corporation
Consumer StaplesMkt cap $32.1BNext earnings Oct 29, 2026
Price
$97.59
Est. fund entry
$109.77-11.1%
Shares held
10.1M
Position value
$1.10B
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
19.3K
150.1K
+677.1%
Renaissance Technologies
1.32M
1.50M
+13.8%
Citadel Advisors
1.19M
1.31M
+10.8%
Two Sigma Investments
5.19M
7.09M
+36.6%
Retail attention 4 of 4 signals quiet
Google Trends21/100quiet
News, 30 days10 articlesquiet
Call/put OI1.00quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Four funds added Kimberly-Clark in Q2-26 — Bridgewater more than seven-folded a small base (+677%), Two Sigma +37%, Renaissance +14%, Citadel +11% — totaling a $1.1B position across the watchlist and the largest aggregate dollar value on this scan. Unlike the other names here, the stock is actually DOWN from the Q2 mark of ~$110 to $98 today, meaning these funds sit modestly underwater. That is a feature, not a bug: when slower-moving managers add on strength and the price then drifts back below their mark, the setup often reflects a structural view (pulp-cost normalization, LatAm pricing stabilization, defensive-staple rotation) rather than a chased momentum trade. Catalyst retail has not priced: the Oct 29 Q3 report finally showing the end of pulp input-cost compression on the Personal Care margin line, which generalist CPG analysts have been missing because their models are anchored to PG and CLX volume/elasticity narratives.
What would prove it wrong
If pulp re-inflects or Huggies share-loss accelerates vs. private label, the quiet-staple thesis breaks. The Oct 29 earnings date sits at the outer edge of the 7-trading-day exclusion window — track whether the admin review surface auto-defers this name on the next scan.
#5
ATO
Atmos Energy Corporation
UtilitiesMkt cap $25.9BNext earnings Nov 4, 2026
Price
$161.66
Est. fund entry
$172.27-6.2%
Shares held
2.40M
Position value
$413.1M
Funds that added
Fund
Prior shares
Shares now
Change
Bridgewater Associates
—
3.59K
New position
Renaissance Technologies
166.8K
447.9K
+168.5%
Citadel Advisors
779.7K
1.76M
+126.2%
Two Sigma Investments
90.0K
183.1K
+103.5%
Retail attention 4 of 4 signals quiet
Google Trends8/100quiet
News, 30 days6 articlesquiet
Call/put OI0.90quiet
Retail hotlistsNot listedquiet
AIWhy these funds may be buying
Four funds added Atmos Energy in Q2-26 with Bridgewater opening a new position and Renaissance, Citadel, and Two Sigma all more than doubling existing stakes. Atmos is a pure-play Texas and midwest regulated natural-gas utility — one of the deepest 'wallpaper' utility names in the S&P. Fund marks sit at ~$172 vs. $162 today, so the watchlist is modestly underwater — again a feature when it signals a structural rate-base growth view (6-8% EPS CAGR) rather than a tactical trade. The catalyst retail has not priced: executive-order expansions to LNG export permitting on the Gulf flow through to higher out-year rate-base assumptions on Atmos's Permian-adjacent gathering and distribution footprint, which the Nov 4 fiscal 2026 year-end print and fiscal 2027 guidance should begin to reflect.
What would prove it wrong
A warmer-than-normal winter compresses realized throughput; adverse Texas rate-case rulings compress the regulated-return path. The stock is sensitive to the long end of the yield curve — a sharp 10Y re-tightening breaks the utility-multiple leg of the thesis before the LNG-permitting leg can carry it.
Based on public SEC 13F filings. Funds file them up to 45 days after each quarter ends, so they show positions at quarter-end, not today. Average entry prices are estimates (filing value ÷ shares) — 13F filings don't report cost basis. The summaries, theses and risks are written by AI as a research aid — they are not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Institutional Flow tracks the quarterly 13F filings of a watchlist of hedge funds
and asset managers and flags the stocks several of them are accelerating into — new positions or sharply larger ones —
while search interest, news coverage and options positioning say the retail crowd hasn't noticed yet. It is free, and a
new scan is posted every Saturday by 9:00 AM ET. How to read Institutional Flow →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.